Rezon Bio Launches Two State-of-the-Art CDMO Facilities for Biologics in Europe

Rezon Bio has debuted as a new contract development and manufacturing organization (CDMO) in Europe, specializing in biologics13.

The company operates two mirrored-capability facilities located in Gdańsk and Warsaw-Duchnice, Poland, which enable seamless technology transfer and flexible scale-up13.

These facilities are based on single-use systems, allowing for faster product turnaround and accelerated delivery timelines1.

Rezon Bio offers a comprehensive path from cell line development through GMP manufacturing to commercial supply23.

Digital innovation forms a central part of the company's approach, utilizing process modeling, AI-enabled systems, and project transparency tools to reduce delays and improve project management1.

The company leverages Poland’s strong biopharma workforce and cost-efficient structure to deliver competitive economics while maintaining high quality standards1.

Rezon Bio builds on its experience with biosimilars, with two launched products already commercialized globally through its partners1.

Both facilities have been audited by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), ensuring compliance with global quality standards1.

Adriana Kiędzierska-Mencfeld is the newly appointed CEO, and Konstantin Matentzoglu is Chairman of the Supervisory Board of Rezon Bio1.

Rezon Bio will present its capabilities at major upcoming industry events including Festival of Biologics, European Biomanufacturing Summit, CPHI Frankfurt, and BIO-Europe1.

Sources:

1. https://www.businesswire.com/news/home/20250929803065/en/Rezon-Bio-Launches-as-a-European-Biologics-CDMO-Combining-Cost-Efficiency-and-Digital-Innovation

2. https://www.contractpharma.com/breaking-news/

3. https://www.fiercepharma.com/manufacturing/new-cdmo-bloc-rezon-bio-debuts-two-plants-tackle-biologics-contract-manufacturing